This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Insider Trading Alert - Cepheid And 4 Others Traded By Insiders

Dendreon (DNDN) - FREE Research Report

Cox Greg who is VP, Finance at DENDREON CORP sold 888 shares at $4.30 per share for a total value of $3,818.40 on July 3, 2013. Following this transaction, the VP, Finance owned 116,979 shares meaning that the stake was reduced by 0.75% with the 888 share sell-off.

Frohlich Mark W who is EVP, R&D and CMO at DENDREON CORP sold 2,564 shares at $4.30 per share for a total value of $11,025.20 on July 3, 2013. Following this transaction, the EVP, R&D and CMO owned 540,994 shares meaning that the stake was reduced by 0.47% with the 2,564 share sell-off.

Schiffman Gregory T who is CFO, EVP of Finance & Treasure at DENDREON CORP sold 2,564 shares at $4.30 per share for a total value of $11,025.20 on July 3, 2013. Following this transaction, the CFO, EVP of Finance & Treasure owned 445,846 shares meaning that the stake was reduced by 0.57% with the 2,564 share sell-off.

The shares most recently traded at $4.49, up $0.01, or 0.22% since the insider transactions.

The average volume for Dendreon has been 4.2 million shares per day over the past 30 days. Dendreon has a market cap of $677.7 million and is part of the health care sector and drugs industry. Shares are down 18.71% year to date as of the close of trading on Friday.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Currently there are 2 analysts that rate Dendreon a buy, 8 analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DNDN - FREE

TheStreet Quant Ratings rates Dendreon as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Dendreon Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs